PALI Stock Overview A clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Palisade Bio, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Palisade Bio Historical stock prices Current Share Price US$1.86 52 Week High US$22.35 52 Week Low US$1.38 Beta 1.31 1 Month Change -18.42% 3 Month Change -45.77% 1 Year Change -77.18% 3 Year Change -99.82% 5 Year Change n/a Change since IPO -99.98%
Recent News & Updates
High number of new and inexperienced directors Jan 02
Palisade Bio, Inc. Appoints Brian G. Feagan to its Clinical Advisory Board Dec 18
Palisade Bio, Inc. Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-To-Severe Ulcerative Colitis Is to Be Safe and Well Tolerated in Treated Subjects Dec 03
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis Nov 22
Price target increased by 33% to US$45.00 Nov 13
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) Nov 08 See more updates
High number of new and inexperienced directors Jan 02
Palisade Bio, Inc. Appoints Brian G. Feagan to its Clinical Advisory Board Dec 18
Palisade Bio, Inc. Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-To-Severe Ulcerative Colitis Is to Be Safe and Well Tolerated in Treated Subjects Dec 03
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis Nov 22
Price target increased by 33% to US$45.00 Nov 13
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) Nov 08
Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis Nov 02 Palisade Bio, Inc. has filed a Follow-on Equity Offering. Oct 31
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis Oct 10
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification Sep 05
New major risk - Financial position Aug 14
Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis Aug 08
Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108 Jul 29
Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product Jul 11
Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024 May 25
Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108 May 23
Price target decreased by 33% to US$22.50 May 22 Palisade Bio, Inc. announced that it has received $3.999943 million in funding May 12
Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors May 08 Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding May 03
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) May 02
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool Apr 17
Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements Mar 28
Palisade Bio, Inc. Announces Advisory Board Appointments Feb 09
New major risk - Share price stability Jan 30 Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million. Jan 27
Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Dec 31 Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Dec 30
New major risk - Revenue and earnings growth Nov 18
Price target decreased by 81% to US$3.00 Oct 27
Palisade Bio Receives Non-Compliance Notice from Nasdaq Oct 21 Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million. Sep 13
Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.
Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions Aug 10
New major risk - Market cap size Aug 10
Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study May 12
Palisade Bio, Inc. Announces Board Appointments Feb 09 Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.220371 million. Jan 06
Palisade Bio, Inc. announced that it has received funding Jan 05
Palisade Bio Regains Compliance with Nasdaq Listing Requirements Dec 02
U.S. Food and Drug Administration Grants Fast Track Designation to Palisade Bio for LB1148 for Accelerated Return of Bowel Function Following GI Surgery Nov 23
Palisade Bio Appoints Herbert B. Slade MD, FAAAAI as Chief Medical Officer Nov 19
Price target decreased to US$3.00 Nov 16
Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer Oct 18
Palisade Bio, Inc. Announces Executive Changes Oct 16
Palisade Bio, Inc. Announces Chief Executive Officer Transition Oct 12
Palisade Bio announces CEO transition Oct 11
Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons Clinical Congress 2022 Sep 30
Palisade Bio, Inc. Announces the Commencement of Patient Enrollment and Dosing in Its Pivotal Phase 3 Study Evaluating LB1148 Sep 16
Palisade Bio streamlines operations, including cutting 20% of employees Sep 15
Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function Aug 18
Palisade Bio GAAP EPS of -$0.12 Aug 15 Palisade Bio, Inc. has completed a Composite Units Offering in the amount of $12 million. Aug 13
Palisade Bio, Inc. Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function Jul 28
Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function Jul 27
Palisade Bio Initiates Phase 3 Study of Lb1148 in Lead Indication for Postoperative Return of Bowel Function Jun 30
Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy Jun 29
Palisade Bio, Inc. Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard May 22 Palisade Bio, Inc. announced a financing transaction May 08
Palisade Bio, Inc. and Newsoara Biopharma Co., Ltd. Receives NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 May 06
Price target decreased to US$4.00 Apr 27
High number of new directors Apr 27
Palisade Bio, Inc., Annual General Meeting, Jun 09, 2022 Apr 22
Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely Mar 28
Palisade Bio, Inc. Appoints Robert McRae as Senior Vice President, Operations and Strategic Development Feb 16
Palisade Bio to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting Feb 09
High number of new and inexperienced directors Nov 16
Palisade Bio: Guarding Intestinal Integrity Nov 07
Palisade Bio, Inc. announced that it has received $5.209141 million in funding from Yuma Regional Medical Center Aug 21
Palisade Bio, Inc. announced delayed 10-Q filing Aug 17
Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery May 14
Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China May 08 Shareholder Returns PALI US Biotechs US Market 7D 5.1% -1.9% -2.8% 1Y -77.2% -5.7% 24.1%
See full shareholder returns
Return vs Industry: PALI underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: PALI underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is PALI's price volatile compared to industry and market? PALI volatility PALI Average Weekly Movement 24.8% Biotechs Industry Average Movement 10.9% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: PALI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PALI's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy.
Show more Palisade Bio, Inc. Fundamentals Summary How do Palisade Bio's earnings and revenue compare to its market cap? PALI fundamental statistics Market cap US$2.19m Earnings (TTM ) -US$14.06m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PALI income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$14.07m Earnings -US$14.06m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -10.58 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 3.6%
How did PALI perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 05:26 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Palisade Bio, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kumaraguru Raja Brookline Capital Markets Aydin Huseynov Ladenburg Thalmann & Company Jason McCarthy Maxim Group
Show 1 more analysts 
